2024-518758-18-02RecruitingPhase 1
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 22 May 2025
- Start date
- 3 Mar 2026
- Lead sponsor
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- EU CT number
- 2024-518758-18-02
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adult volunteers to test the safety and tolerability of DS101 eye drops and how the body handles them.
- Age
- 18 years or older
- Sex
- Men and women can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.